ID   INT-MEL-15/2
AC   CVCL_C672
SY   Me1402; ME1402; ME 1402; Me 1402; Me1402/R; Me1402r; Me1402/P
DR   cancercelllines; CVCL_C672
DR   Cosmic; 720625
DR   Cosmic; 889007
DR   Cosmic; 928698
DR   Wikidata; Q54897760
RX   DOI=10.1007/0-306-46872-7_16;
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RX   PubMed=2469723;
RX   PubMed=2776368;
RX   PubMed=7520026;
RX   PubMed=8459226;
RX   PubMed=8980186;
RX   PubMed=9354451;
RX   PubMed=9973437;
RX   PubMed=15048078;
RX   PubMed=22383533;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 20
//
RX   DOI=10.1007/0-306-46872-7_16;
RA   Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.;
RT   "Melanoma: the Milan melanoma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999).
//
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RA   Grazia G.;
RT   "Co-targeting of oncogenic and death receptors pathways in human
RT   melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic
RT   strategy.";
RL   Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy.
//
RX   PubMed=2469723; DOI=10.4049/jimmunol.142.10.3692;
RA   Anichini A., Mazzocchi A., Fossati G., Parmiani G.;
RT   "Cytotoxic T lymphocyte clones from peripheral blood and from tumor
RT   site detect intratumor heterogeneity of melanoma cells. Analysis of
RT   specificity and mechanisms of interaction.";
RL   J. Immunol. 142:3692-3701(1989).
//
RX   PubMed=2776368; DOI=10.1007/BF01753674;
RA   Larizza L., Doneda L., Rodolfo M., Fossati G.;
RT   "High incidence of chromosomal lesions involving C-heterochromatin in
RT   four human melanoma lines.";
RL   Clin. Exp. Metastasis 7:633-644(1989).
//
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
//
RX   PubMed=8459226; DOI=10.1084/jem.177.4.989; PMCID=PMC2190978;
RA   Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A.,
RA   Squarcina P., Herlyn M., Parmiani G.;
RT   "Melanoma cells and normal melanocytes share antigens recognized by
RT   HLA-A2-restricted cytotoxic T cell clones from melanoma patients.";
RL   J. Exp. Med. 177:989-998(1993).
//
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=9973437; DOI=10.4049/jimmunol.162.3.1739;
RA   Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L.,
RA   Ravagnani F., Gallino F., Belli F., Parmiani G.;
RT   "Novel HLA-Cw8-restricted T cell epitopes derived from
RT   tyrosinase-related protein-2 and gp100 melanoma antigens.";
RL   J. Immunol. 162:1739-1748(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//